MktsMarkets

Cellectis S.A.
NASDAQ: CLLSKey statistics
CLLS News
Stories mentioning CLLS from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q2 '23Jun 30 |
|---|---|
| Income Statement | |
| Revenue | |
| Cost of Goods Sold | |
| Gross Profit | 0.00 |
| Operating Expenses | |
| Research & Development | |
| Sales General & Admin | |
| Total Operating Expenses | |
| Operating Income (Loss) | |
| Interest Income | |
| Interest Expense | |
| Other Expense | |
| Pretax Income | |
| Tax Provision | |
| Net Income (Loss) | |
| Earnings Per Share (Basic) | (0.20) |
| Earnings Per Share (Diluted) | (0.20) |
| Weighted Average Shares Outstanding (Basic) | |
| Weighted Average Shares Outstanding (Diluted) |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About CLLS
Cellectis S.A. (NASDAQ: CLLS) is a stock listed on the Nasdaq Stock Market under the ticker symbol CLLS. It last traded at $1.03 (Nov 18, 2026, 4:00 PM ET), down 2.8% on the day. That gives Cellectis a market capitalisation of $73.3M.
Over the past 52 weeks CLLS has traded between $0.9000 and $4.75.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…